Across TCGA pan-cancer cohorts, PTPRCAP mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTPRCAP data layer compared with 1 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PTPRCAP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PTPRCAP expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where PTPRCAP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.812	0.523	.003	14	view →
CCRCC	OS	Tertile	II,III,IV	1.000	0.708	.003	9	view →
HNSC	DFS	Tertile	II,III,IV	0.933	1.000	.028	2	view →
LSCC	OS	Tertile	II,III,IV	0.563	0.845	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PTPRCAP tumor-vs-normal RNA expression · all PTPRCAP data types